This project has been shortlisted for the DPH 2025 Innovation Prize – Best Data Driven Innovation
Team: Frederico Stock, Francisco Nogueira and Guilherme Stock (Glooma Lda.)
Outline: Glooma is a Portuguese startup dedicated to transforming breast cancer prevention through a user-centered approach supported by medical innovation and artificial intelligence. Our solution, the SenseGlove, is a glove equipped with pressure sensors connected to a mobile app. This system allows any woman to perform guided and standardized breast self-examinations, with an intelligent analysis that helps detect abnormalities more reliably and earlier.
What sets our innovation apart is how we leverage data to create value for both users and healthcare professionals. Through the mobile app, we collect real-time sensor data during examinations and combine it with clinical and contextual information provided by the users. This data is analyzed by machine learning algorithms, and generates personalized outcomes, follow-up suggestions, and reminders to ensure regular screening.
A core element of Glooma’s data-driven innovation is the risk assessment tool integrated into the app. This tool evaluates factors such as family history, genetic mutations (like BRCA), age, lifestyle habits, and reported symptoms, classifying the risk level and personalizing follow-up recommendations. This not only promotes health literacy, but also optimizes clinical triage, enabling physicians to identify high-risk users who may benefit from further diagnostic testing.
In addition, Glooma’s solution is aligned with principles of interoperability, privacy, and data protection. All information is encrypted and stored in compliance with GDPR, and it is only shared with healthcare professionals with the user’s consent. This ensures a secure and transparent data-sharing ecosystem, which is key to building public trust in digital health technologies.
Glooma has already completed pilots with over 100 users and initiated clinical trials with multiple hospital institutions. We are now planning to enter the U.S. market with a B2B2C business model, focused on companies offering health benefits to high-risk female employees.
Our data-driven approach enables us to scale impact while promoting accessible, empowered, and personalized prevention. Glooma does not aim to replace clinical exams, but rather to fill the gap between neglect and early detection, where the right data, at the right time, can save lives.
